Amy Williams
Global Head of Clinical Development, Medical Affairs, & Clinical Operations Biovica
Seminars
Thursday 8th October 2026
Beyond Maximum Tolerated Dose: Using a Dynamic Pharmacodynamic Biomarker, TKa, for Oncology Drug Development
12:40 pm
- Explore how longitudinal TKa can provide an early functional readout of biological drug activity and pathway suppression
- See clinical Phase 1 data from BTX-9341 illustrating how TKa was incorporated into development of a next-generation CDK4/6 degrader
- Learn how dynamic proliferation monitoring can support biologically informed dose optimization, patient stratification, and development decisions
